Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report

被引：1

作者：

Matsuura, Hiroaki ^{[1
]}

Higo, Hisao ^{[1
]}

Kuribayashi, Tadahiro ^{[1
]}

Tamaoki, Akihiko ^{[2
]}

Nakasuka, Takamasa ^{[1
]}

Uno, Mari ^{[1
]}

Makimoto, Go ^{[1
]}

Ninomiya, Kiichiro ^{[1
]}

Fujii, Masanori ^{[1
]}

Rai, Kammei ^{[1
]}

Ichihara, Eiki ^{[1
]}

Hotta, Katsuyuki ^{[1
]}

Miyahara, Nobuaki ^{[1
]}

Tabata, Masahiro ^{[1
]}

Maeda, Yoshinobu ^{[3
]}

Kiura, Katsuyuki ^{[1
]}

Ohashi, Kadoaki ^{[1
]}

机构：

[1] Okayama Univ Hosp, cho Kita Ward, 2 5 1 Shikata cho Kita Ward, Okayama 7008558, Japan

[2] Okayama Hlth Fdn Hosp, Okayama Hlth Fdn, Okayama 7000952, Japan

[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med, Okayama, Japan

来源：

THORACIC CANCER | 2024年 / 15卷 / 17期

关键词：

case report; EGFR-mutated lung cancer; osimertinib; pulmonary tuberculosis; rifampicin; GEFITINIB;

D O I：

10.1111/1759-7714.15324

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well-established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89-year-old female, diagnosed with epidermal growth factor receptor (EGFR)-mutant lung cancer and pulmonary tuberculosis. Accumulating evidence is warranted to develop an optimal treatment strategy for patients with lung cancer and tuberculosis.

引用

页码：1390 / 1394

页数：5

共 50 条

[21] Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib
White, M.
Neal, J. W.
Gardner, R. M.
Cunanan, K. M.
Das, M.
Padda, S. K.
Ramchandran, K.
Chen, T. T.
Wakelee, H.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S773 - S774
[22] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
Soria, J. -C.
Ohe, Y.
Vansteenkiste, J.
Reungwetwattana, T.
Chewaskulyong, B.
Lee, K. H.
Dechaphunkul, A.
Imamura, F.
Nogami, N.
Kurata, T.
Okamoto, I.
Zhou, C.
Cho, B. C.
Cheng, Y.
Cho, E. K.
Voon, P. J.
Planchard, D.
Su, W. -C.
Gray, J. E.
Lee, S. -M.
Hodge, R.
Marotti, M.
Rukazenkov, Y.
Ramalingam, S. S.
Boyer, Michael
Lee, Chee
Hughes, Brett
O'Byrne, Kenneth
Briggs, Peter
Milward, Michael
John, Thomas
Demedts, Ingel
Vansteenkiste, Johan
Bustin, Frederique
Barrios, Carlos Henrique
Timcheva, Constanta
Butts, Charles
Goss, Glenwood
Juergens, Rosalyn
Leighl, Natasha
Cheng, Susanna
Burkes, Ronald
Zhou, Caicun
Zhang, Helong
Shu, Yongqian
Cheng, Ying
Zhou, Qing
Li, Wei
Feng, Guosheng
He, Yong
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 113 - 125
[23] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Leonetti, Alessandro
Sharma, Sugandhi
Minari, Roberta
Perego, Paola
Giovannetti, Elisa
Tiseo, Marcello
BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 725 - 737
[24] EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report
Dansin, Eric
Carnot, Aurelien
Servent, Veronique
Daussay, Dorothee
Robin, Yves-Marie
Surmei-Pintilie, Ecaterina
Lauridant, Geraldine
Descarpentries, Clothilde
Revillion, Francoise
Delattre, Claire
CASE REPORTS IN ONCOLOGY, 2015, 8 (01): : 164 - 168
[25] Novel LZTR1 germline mutation as a mechanism of resistance to osimertinib in EGFR-mutated lung adenocarcinoma: a case report
Park, Wai
Fricke, Jeremy
Mambetsariev, Isa
Velasquez, Giovanny
Nadaf-Rahrov, Reza
Dingal, Shaira Therese
Kim, Pauline
Babikian, Razmig
Amini, Arya
Afkhami, Michelle
Salgia, Ravi
TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (02) : 625 - 630
[26] Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer
Tan, W. L.
Tan, S. H.
Tan, D. S. W.
Lai, G. G. Y.
Ang, M. -K.
Jain, A.
Kanesvaran, R.
Rajasekaran, T.
Saw, S. P. L.
Teh, Y. L.
Chan, J.
Ng, Q. S.
Lim, D. W. -T.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S652 - S653
[27] Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib
Taronna, Gianluca
Leonetti, Alessandro
Dall'Olio, Filippo Gustavo
Rizzo, Alessandro
Parisi, Claudia
Buti, Sebastiano
Bordi, Paola
Brocchi, Stefano
Golfieri, Rita
Ardizzoni, Andrea
Sverzellati, Nicola
Tiseo, Marcello
TUMORI JOURNAL, 2022, 108 (06): : 592 - 599
[28] Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
Aredo, Jacqueline, V
Wakelee, Heather A.
Neal, Joel W.
Padda, Sukhmani K.
CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 30
[29] The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells
Lee, Tae-Gul
Kang, Hye-Min
Kim, Seo Yun
Kim, Hye-Ryoun
Kim, Cheol Hyeon
EXPERIMENTAL CELL RESEARCH, 2023, 430 (01)
[30] Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
Merkhofer, Cristina M.
Baik, Christina S.
JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (06):

← 1 2 3 4 5 →